Opa3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| OPA3 - OPA3 mitochondrial outer membrane protein |
|---|
| Gene Symbol | OPA3 |
| Full Name | OPA3 mitochondrial outer membrane protein |
| Chromosomal Location | 19q13.32 |
| NCBI Gene ID | 80207 |
| OMIM | 606580 |
| Ensembl ID | ENSG00000142046 |
| UniProt ID | Q9H3K1 |
| Associated Diseases | Optic atrophy with cataract |
This section provides a comprehensive overview of the gene/protein and its role in the nervous system and neurodegenerative diseases.
The OPA3 gene (Optic Atrophy 3) encodes a mitochondrial outer membrane protein that plays critical roles in mitochondrial dynamics, cellular metabolism, and neuronal survival. The OPA3 protein is primarily localized to the mitochondrial outer membrane, where it participates in mitochondrial fusion, cristae maintenance, and regulation of mitochondrial morphology.
OPA3 is essential for proper mitochondrial fusion:
- Interacts with mitofusins (MFN1, MFN2) to regulate outer membrane fusion
- Helps maintain mitochondrial network integrity
- Supports mitochondrial DNA (mtDNA) maintenance
- Regulates mitochondrial cristae structure
Beyond fusion, OPA3 participates in:
- Lipid metabolism: Influences cardiolipin distribution
- Apoptosis regulation: Modulates BAX/BAK-dependent apoptosis
- Iron-sulfur cluster assembly: Connected to Fe-S cluster biogenesis
- Cellular stress response: Activated under mitochondrial stress
OPA3 mutations cause Type I 3-methylglutaconic aciduria, characterized by:
- Elevated 3-methylglutaconic acid in urine
- Optic atrophy
- Cataracts
- Hearing loss
- Developmental delay
- Neurological involvement
Autosomal recessive OPA3 mutations lead to:
- Progressive vision loss
- Bilateral optic nerve atrophy
- Early-onset cataracts
- Often presenting in childhood
OPA3 dysfunction may contribute to:
- Increased susceptibility to Parkinson's disease
- Mitochondrial dysfunction in Alzheimer's disease
- Amyotrophic lateral sclerosis (ALS)
- Age-related neurodegeneration
- Highest expression in: optic nerve, retina, brain cortex
- Moderate expression: hippocampus, cerebellum
- Lower expression in other brain regions
- Neurons (particularly vulnerable)
- Retinal ganglion cells
- Astrocytes
- Oligodendrocytes
- Expressed throughout development
- Critical during periods of high metabolic demand
- Maintained in adult tissues
OPA3 interacts with several key proteins:
- MFN1/MFN2: Mitofusins for mitochondrial fusion
- OPA1: Inner membrane fusion regulator
- BAX/BAK: Apoptosis execution
- TOM complex: Mitochondrial protein import
- Genetic testing for OPA3 mutations
- Urine organic acid analysis (3-MGA)
- Ophthalmologic examination
- MRI brain imaging
- No curative treatment available
- Supportive care for symptoms
- Physical therapy
- Genetic counseling
- Research into mitochondrial-targeted therapies
Current research focuses on:
- Understanding OPA3 function in neuronal cells
- Developing mitochondrial-targeted therapeutics
- Gene therapy approaches
- Biomarker development for 3-MGA
The study of Opa3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- OPA3 mutations cause 3-methylglutaconic aciduria (2005)
- Mitochondrial dynamics and optic atrophy (2018)
- OPA3 function in mitochondrial fission (2019)
- 3-Methylglutaconic aciduria: clinical spectrum (2020)
- Mitochondrial dysfunction in neurodegeneration (2021)
- OPA3 and retinal ganglion cell survival (2022)
- Targeting mitochondria in neurodegenerative diseases (2023)
- Gene therapy for mitochondrial disorders (2024)